Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
Jun 23, 2025, 10:58 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The significant improvement in overall survival from the STELLAR-303 trial bolsters market confidence. This positive data increases expectations for zanzalintinib's commercial potential, similar to how positive trial results have historically driven biotech stock prices up, such as the case with CAR-T therapies upon positive clinical trial announcements.
AI summary
What happened, with direct paths to the underlying reporting
Exelixis announced positive STELLAR-303 trial results for zanzalintinib. Zanzalintinib increased overall survival compared to regorafenib in metastatic CRC. Analysts project U.S. peak sales of $875 million for zanzalintinib. Cabometyx regulatory approval in Europe anticipated in 2025. EXEL stock rose 11.1% to $44.85 following the announcement.
Exelixis announced positive STELLAR-303 trial results for zanzalintinib.
Zanzalintinib increased overall survival compared to regorafenib in metastatic CRC.
Analysts project U.S. peak sales of $875 million for zanzalintinib.
Cabometyx regulatory approval in Europe anticipated in 2025.
EXEL stock rose 11.1% to $44.85 following the announcement.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
EXEL stock fell 12.17% following STELLAR-303 Phase 3 trial results. The trial showed a 20% reduction in death risk with zanzalintinib. Median overall survival was 10.9 months vers…
